Overview

Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis

Status:
Recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
Jaktinib Dihydrochloride Monohydrate for idiopathic pulmonary fibrosis
Phase:
Phase 2
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Treatments:
Acetylcysteine
N-monoacetylcystine